|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.70 EUR | +1.83% |
|
+5.84% | +11.64% |
| 16/06 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
| 10/06 | Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading | MT |
Company Valuation: Zai Lab Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,059 | 2,946 | 2,688 | 2,853 | 1,962 | 2,148 | - | - |
| Change | - | -51.37% | -8.77% | 6.15% | -31.23% | 9.5% | - | - |
| Enterprise Value (EV) 1 | 4,650 | 1,938 | 1,897 | 2,095 | 1,397 | 1,705 | 1,761 | 1,934 |
| Change | - | -58.33% | -2.13% | 10.47% | -33.34% | 22.09% | 3.28% | 9.81% |
| P/E | -8.29x | -6.63x | -7.9x | -10.1x | -11x | -8.63x | -10.3x | -14.2x |
| PBR | 4.35x | - | 3.34x | 3.36x | 2.73x | 4.02x | 4.32x | 4.28x |
| PEG | - | 0.2x | 0.3x | 0.4x | 0.3x | -0.2x | 0.7x | 0.5x |
| Capitalization / Revenue | 42x | 13.7x | 10.1x | 7.15x | 4.26x | 4.79x | 3.61x | 2.84x |
| EV / Revenue | 32.2x | 9.01x | 7.11x | 5.25x | 3.04x | 3.8x | 2.96x | 2.56x |
| EV / EBITDA | -6.7x | -4.89x | -5.3x | -7.75x | -6.51x | -7.02x | -11x | -29x |
| EV / EBIT | -6.64x | -4.79x | -5.17x | -7.43x | -6.09x | -6.59x | -10.1x | -22.5x |
| EV / FCF | -8.19x | -4.94x | -9.23x | -9.5x | -8.5x | -9.7x | -15.2x | -27.5x |
| FCF Yield | -12.2% | -20.2% | -10.8% | -10.5% | -11.8% | -10.3% | -6.58% | -3.63% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.58 | -4.63 | -3.46 | -2.6 | -1.6 | -2.215 | -1.865 | -1.347 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 144.3 | 215 | 266.7 | 399 | 460.2 | 448.7 | 595.6 | 755.9 |
| EBITDA 1 | -693.6 | -396.1 | -357.5 | -270.3 | -214.4 | -243 | -159.9 | -66.57 |
| EBIT 1 | -700.1 | -404.4 | -366.6 | -282.1 | -229.4 | -258.7 | -173.7 | -85.83 |
| Net income 1 | -704.5 | -443.3 | -334.6 | -257.1 | -175.5 | -240.9 | -156.5 | -125.8 |
| Net Debt 1 | -1,409 | -1,008 | -791.3 | -757.9 | -565.3 | -443.1 | -387.2 | -214.4 |
| Reference price 2 | 62.85 | 30.70 | 27.33 | 26.19 | 17.64 | 19.12 | 19.12 | 19.12 |
| Nbr of stocks (in thousands) | 96,409 | 95,972 | 98,349 | 1,08,937 | 1,11,219 | 1,12,355 | - | - |
| Announcement Date | 01/03/22 | 01/03/23 | 27/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 16.94x | 3.69x | 9.97x | 0.6% | 6.66TCr | |
| 28.53x | 5.87x | 17.23x | 0.55% | 5.76TCr | |
| 34.88x | 11.82x | 22.38x | -.--% | 4.22TCr | |
| -43.93x | 3.11x | 9.2x | 3.49% | 3.91TCr | |
| 34.9x | 3.71x | 11.39x | -.--% | 3.19TCr | |
| -9.24x | 13.4x | -8.22x | -.--% | 3.16TCr | |
| 16.96x | 3.25x | 9.83x | -.--% | 2.33TCr | |
| 53.7x | 5.97x | 40.99x | -.--% | 1.89TCr | |
| 26.89x | 5.5x | 14.75x | -.--% | 1.72TCr | |
| Average | 17.74x | 6.26x | 14.17x | 0.52% | 3.65TCr | |
| Weighted average by Cap. | 15.90x | 6.18x | 13.16x | 0.63% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ZLAB Stock
- 1ZL Stock
- Valuation Zai Lab Limited
Select your edition
All financial news and data tailored to specific country editions
